Lipidomics and anti-trypanosomatid chemotherapy

Area of Science:

• Parasitology
• Biochemistry
• Drug Discovery

Background:

• Kinetoplastida parasites (Leishmania, Trypanosoma brucei, Trypanosoma cruzi) cause significant human and animal diseases.
• Current treatments are inadequate due to drug resistance, necessitating new therapeutic strategies.
• Lipids play crucial roles in cellular functions, and advancements in lipidomics offer new avenues for research.

Purpose of the Study:

• To review the application of lipidomics in understanding kinetoplastid parasites.
• To identify unique lipid species and metabolic pathways as potential drug targets.
• To explore the role of lipidomics in deciphering drug mechanisms and resistance.

Main Methods:

• Characterization of kinetoplastid lipidomes and subcellular lipid content using lipidomics.
• Identification of unique lipid species and metabolic pathways for drug targeting.
• Utilizing genetically modified microorganisms to study lipid metabolism enzymes.
• Investigating the impact of anti-microbial drugs on lipid metabolism.

Main Results:

• Lipidomics has expanded knowledge of lipid metabolism in trypanosomatids.
• Unique lipid targets and pathways have been identified for potential drug development.
• Insights into drug mechanisms and resistance related to lipid metabolism have been gained.

Conclusions:

• Lipidomics provides a foundation for developing improved anti-parasitic pharmaceuticals.
• Understanding lipid metabolism is key to combating drug resistance in trypanosomatids.
• Lipidomics enhances our knowledge of pathogen-host interactions and drug efficacy.